STCUBE Logo

STCUBE

Develops immuno-oncology therapies targeting novel immune checkpoints for cancer.

052020 | KO

Overview

Corporate Details

ISIN(s):
KR7052020005
LEI:
Country:
South Korea
Address:
서울특별시 강남구 영동대로 511 2201(삼성동, 무역센터 트레이드타워), 강남구

Description

STCube is a biopharmaceutical company specializing in the research and development of innovative immuno-oncology therapies. The company focuses on discovering treatments that target novel immune checkpoints to overcome cancer's immune evasion mechanisms. Its primary area of research involves BTN1A1, a novel immune checkpoint target often expressed in a mutually exclusive manner with PD-L1. STCube's lead drug candidate, Nelmastobart, is a first-in-class anti-BTN1A1 immune checkpoint inhibitor. This therapy is being developed to provide a new treatment option for patients with treatment-resistant, refractory, or recurrent cancers that have limited therapeutic alternatives. The company utilizes a precision-medicine, biomarker-driven approach in its clinical development programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
기업설명회(IR)개최
Korean 7.2 KB
2025-08-25 00:00
투자판단관련주요경영사항(임상시험계획자진취하등) (면역항암제 hSTC810 의 미국 식품의약국(FDA) 제1b/2상 임상…
Korean 14.5 KB
2025-08-25 00:00
투자판단관련주요경영사항(임상시험계획승인신청) (Nelmastobart(hSTC810)의 진행성/전이성 비소세포폐암 제2…
Korean 9.1 KB
2025-08-14 00:00
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.2 MB
2025-06-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-20 00:00
투자판단관련주요경영사항(임상시험계획승인신청등결정) (면역항암제 Nelmastobart(hSTC810)의 전이성/재발성 …
Korean 13.1 KB
2025-03-19 00:00
정기주주총회결과
Korean 29.9 KB
2025-03-19 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.7 KB
2025-03-11 00:00
감사보고서제출
Korean 25.6 KB
2025-03-11 00:00
사업보고서 (2024.12)
Korean 504.8 KB
2025-03-04 00:00
[기재정정]의결권대리행사권유참고서류
Korean 190.4 KB
2025-02-28 00:00
주주총회소집공고
Korean 202.3 KB
2025-02-28 00:00
의결권대리행사권유참고서류
Korean 186.5 KB

Automate Your Workflow. Get a real-time feed of all STCUBE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for STCUBE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for STCUBE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.